New trial
Spotlight
Phase 2/3 Izalontamab Brengitecan EGFR/HER3 bispecific ADC in metastatic urothelial cancer
- Trial ID
- NCT07106762 on ClinicalTrials.gov
- Cancer type
- Urothelial Carcinoma
- Stage of research
- Registrational
- Location
- Global, multicenter
- Published in
- New in Oncology - Aug 22, 2025
This study, sponsored by Bristol-Myers Squibb and conducted at multiple international sites, is evaluating a novel ADC targeting EGFR/HER3 (BMS-986507) against standard platinum-based chemotherapy (cisplatin, gemcitabine, and carboplatin) in participants with advanced metastatic urothelial carcinoma who have progressed following immunotherapy.
More in bladder and urothelial cancer
-
Trial result · Oct 15, 2026 · NCT04179162
GemBCG (intravesical gemcitabine + BCG immunostimulation) delivers 96% 6‑mo CR in BCG-exposed high‑grade NMIBC -
Trial result · Oct 15, 2026 · NCT02773849
TAR-200 (intravesical gemcitabine device) vs nadofaragene firadenovec: no statistically significant CR durability difference detected through 24 months in BCG-unresponsive CIS -
New trial · Oct 15, 2026 · NCT07827612
Phase 2 FORAY tests selective FGFR3 inhibition with vepugratinib in low-grade bladder and upper tract urothelial tumors -
New trial · Oct 8, 2026 · NCT07815665
Phase 2/3 Ivonescimab PD-1×VEGF bispecific antibody plus enfortumab vedotin Nectin-4 ADC in la/mUC -
New trial · Oct 8, 2026 · NCT07822373
Phase 2 enfortumab vedotin Nectin-4 ADC (MMAE tubulin payload) plus pembrolizumab PD-1 antibody